<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="308225">
  <stage>Registered</stage>
  <submitdate>22/07/2009</submitdate>
  <approvaldate>27/07/2009</approvaldate>
  <actrnumber>ACTRN12609000621213</actrnumber>
  <trial_identification>
    <studytitle>Does Nerve Block Reduce Shoulder Pain Following Stroke?</studytitle>
    <scientifictitle>Does Suprascapular Nerve Block Reduce Shoulder Pain Following Stroke: A single-blind randomised controlled trial with measured outcome assessment.</scientifictitle>
    <utrn />
    <trialacronym>N/A</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Stroke</healthcondition>
    <conditioncode>
      <conditioncode1>Stroke</conditioncode1>
      <conditioncode2>Haemorrhagic</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The intervention group will receive injection into the arm of suprascapular nerve blocking (using depo-medrol 40mg and 0.5% bupivivocaine hydrochloride).</interventions>
    <comparator>The control group will receive 5ml normal saline infiltrated subcutaneously after the 2ml subcutaneous 1% lidocaine infiltration.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Visual Analogue Scale (VAS) to assess for shoulder pain.</outcome>
      <timepoint>Baseline, 1, 4, 12 weeks following injection.
Change in Visual Analogue Scale of pain in comparison to baseline</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Croft Disability Questionnarie</outcome>
      <timepoint>Baseline 1, 4, 12 weeks following injection.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Modified Rankin Scale - Functional disability associated with shoulder pain</outcome>
      <timepoint>Baseline, 1, 4, 12 weeks following injection.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Euroquol Questionnaire - Quality of life</outcome>
      <timepoint>Baseline, 1, 4 &amp; 12 weeks following injection.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion criteria will be all willing patients aged over 18 years and able to give consent with a diagnosis of acute stroke with the previous 12 months and onset of hemiplegic shoulder pain post stroke with a visual analogue scale score of &gt;30mm (100mm scale)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Cognitive deficit that preclude patients  
from reliably using subjective outcome   measures scales  - Mini-Mental State Examination (MMSE) &lt; 23.

Language deficits (inability to follow 2-
stage command) or limited English language that preclude patients from reliably using subjective outcome measures scales

Allergy to proposed injection agents (depo-medrol 40mg and 0.5% bupivocaine hydrocholoride)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Following consent and baseline measures particpants will be randomized to receive suprascapular nerve block or placebo injection. Allocation will be managed by a pharmacist external to the project.</concealment>
    <sequence>Simple randomisation - computer generated by a software program</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>11/06/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>66</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Maria Crotty</primarysponsorname>
    <primarysponsoraddress>Repartriation General Hospital
Daws Road, Daw Park, SA, 5041</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Flinders University</fundingname>
      <fundingaddress>Flinders Drive, Bedford Park, SA 5043</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Shoulder pain is a common and debilitating symptom for a large number of people following a stroke.  The cause of shoulder pain is usually related to several factors, including trauma, inflammation and positioning.  In cases when shoulder pain is unable to be prevented, current treatment options include arm supports, physiotherapy techniques, and simple analgesic medication.

It is commonly observed that shoulder pain persists or is inadequately controlled by these interventions.  This research aims to study the effect of an injection that numbs the nerve (Suprascapular Nerve) that supplies pain fibres to the shoulder.  The technique has previously been proven safe and effective in the treatment of shoulder pain associated with rheumatoid arthritis and degenerative shoulder conditions.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Queen Elizabeth Hospital Research and Ethics Committee</ethicname>
      <ethicaddress>28 Woodville Road,
Woodville South, SA, 5011</ethicaddress>
      <ethicapprovaldate>21/04/2009</ethicapprovaldate>
      <hrec>2009031</hrec>
      <ethicsubmitdate>23/03/2009</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital Research Ethics Committee</ethicname>
      <ethicaddress>North Terrace,
Adelaide, SA, 5000</ethicaddress>
      <ethicapprovaldate>7/05/2009</ethicapprovaldate>
      <hrec>090325</hrec>
      <ethicsubmitdate>19/03/2009</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Repatriation General Hospital Human Research and Ethics Committee</ethicname>
      <ethicaddress>Daws Road,
Daw Park, SA, 5941</ethicaddress>
      <ethicapprovaldate>27/04/2009</ethicapprovaldate>
      <hrec>9/09/</hrec>
      <ethicsubmitdate>18/03/2009</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Flinders Clinical Research Ethics Committee</ethicname>
      <ethicaddress>Flinders Medical Centre 
Bedford Park, SA, 5042</ethicaddress>
      <ethicapprovaldate>7/04/2009</ethicapprovaldate>
      <hrec>61/09</hrec>
      <ethicsubmitdate>3/03/2009</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Zoe Adey Allen</name>
      <address>Department of Rehabilitation &amp; Aged Care 
Repatriation General Hospital
Daws Road, Daw Park, SA 5041</address>
      <phone>+61 8 8276 9666</phone>
      <fax>+61 8 8275 1130</fax>
      <email>zoe.allen@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Zoe Adey Allen</name>
      <address>Department of Rehabilitation &amp; Aged Care 
Repatriation General Hospital
Daws Road, Daw Park, SA 5041</address>
      <phone>+61 8 8276 9666</phone>
      <fax>+61 8 8275 1130</fax>
      <email>zoe.allen@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Cara McGrain</name>
      <address>Department of Rehabilitation &amp; Aged Care 
Repatriation General Hospital
Daws Road, Daw Park, SA 5041</address>
      <phone>+61 8 8275 1602</phone>
      <fax>+61 8 8275 1130</fax>
      <email>cara.mcgrain@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>